IFE

Lab Automation Networks Proliferating

Although it may still seem radically innovative in the context of many clinical laboratories, automated production in the manufacturing sector had been the norm for many years. In automobile assembly, for example, automated lines fabricate sub-assemblies and entire vehicles with only occasional human oversight. The result has been vastly improved products, far fewer defects, and significant p...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial

Provides Update to Timeline for Second Pivotal Phase 3 Trial CL-05 CHICAGO, July 02, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced the confirmation ofsupplemental efficacy data from Trial CL-06, the first of twopivotal Phase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatme...

Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced that it will host aconference call and live webcast at 10:00 am (EDT) on Monday, July2, 2007 to discuss data from Trial CL-06, the first of two pivotalPhase 3 clinical trials designed to assess the safety andeffectiveness of cethromycin, a novel once-a-day antibiotic, forthe treatment...

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference

BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that HepaLife's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-PreservationFunctional Recovery of Peripheral Blood Stem Cells for CancerTherapy BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLifeSolutions Inc. , a leading developer and marketer of proprietaryhypothermic storage and cryopreservation media products for cells,tissues, and organs, today presented data from an independent...

Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry

MIAMI--(BUSINESS WIRE)--Jun 21, 2007 - Answerthink, Inc. (NASDAQ:ANSR) announced today that it has formed a strategic alliance withLORENZ Life Sciences Group for the distribution of LORENZ solutionsin North America. Answerthink and LORENZ Life Sciences Group willserve midsize companies by integrating best practice submissionsmanagement solutions into Answerthink's Life Science solutionsbase...

First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex

Anastrozole (ArimidexTM) improves overall survival inpostmenopausal women with early breast cancer receiving treatmentwith tamoxifen – Survival benefit demonstrated for an AI over tamoxifenin a single trial – LUTON, England, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be signific...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...

HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting

BOSTON--(BUSINESS WIRE)--May 29, 2007 - HepaLife Technologies, Inc.(OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce ascientific presentation of its cell based PBS-1 technology forpotential influenza vaccine production at the "Options for theControl of Influenza VI Conference," to be held June 17-23, 2007,in Toronto, Canada. Entitled "High titer growth of human and avian influenz...

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia

Six-Month Data Show Bifeprunox Maintained StabilitySignificantly Longer than Placebo and had a Favorable Weight andLipid Profile Comparable with Placebo MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - SolvayPharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth(NYSE:WYE), and Lundbeck A/S presented clinical study results onbifeprunox, an investigational treatment for...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

UC's Overall Psychological Toll Is Greater Than for Asthma,Rheumatoid Arthritis and Migraines WAYNE, Pa., May 17, 2007 /PRNewswire/ -- Nearly three out offour ulcerative colitis (UC) sufferers (73 percent) responding to anew nationwide survey say not feeling well has become a normal partof life. Furthermore, they describe UC as disruptive when it comesto their relationship with a spouse (...

Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ --Viragen, Inc. and Viragen International, Inc. today announcedresults from a sponsored in vitro study conducted at UmeaUniversity in Sweden, which found that Multiferon(R) (multi-subtype, human alpha interferon) suppressed development ofresistant human melanoma clones to a far greater degree thanrecombinant alpha interferon. The stud...

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg DosageLevel HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ --Boston Life Sciences announced today that clinical data on its leadnerve repair therapy, Cethrin(R), were presented in the Neurotraumaand Critical Care Scientific Session at the 75th Annual Meeting ofthe American Association of Neurological Surgeons (AANS) inWash...

Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo

COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , SolvayPharmaceuticals, Inc. and Lundbeck A/S presented clinical studyresults on bifeprunox at an international medical congress thisweek. Safety analyses suggest bifeprunox, an investigationaltreatment for adult patients diagnosed with schizophrenia, wasassociated with a favorable weig...

Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span

MELBOURNE, Australia, March 23, 2007 /PRNewswire/ -- Scientistsat WEHI have made a discovery with potentially profoundimplications for the care of patients, especially those undergoingcancer chemotherapy. The research team led by Drs Benjamin Kile and David Huang hasdiscovered that platelet life span is controlled by two keymolecules. The discovery raises the prospect of developing...